People
Dr. Anikeeva, a neural engineer, is an Associate Investigator at the McGovern Institute for Brain Research at Massachusetts Institute of Technology (MIT). She’s an Associate Professor of Materials Science, Engineering, and Brain and Cognitive Sciences as well as an Associate Director of the Research Laboratory of Electronics.
Medigene AG announced that its Supervisory Board has appointed Axel-Sven Malkomes as Chief Financial Officer and Chief Business Development Officer effective 1 April 2019.
In an exclusive interview with BioSpace, Iovance CEO Maria Fardis said the company’s goal is to add headcount to support its growth strategy. The company currently has about 100 full-time employees.
When biotech companies post openings for new positions, hiring managers often face the immense task of sorting through numerous resumes of qualified candidates. However, in South Korea, hiring managers are facing a different problem – a dearth of qualified candidates.
Alexander (Sasha) Opotowsky, associate professor at Harvard Medical School and a cardiologist at Boston Children’s Hospital and Brigham and Women’s Hospital took time out to speak with BioSpace about advances in heart health, congenital heart disease (CHD), biopharma, and the Adult Congenital Heart Association (ACHA).
Thomas Wicks, chief strategy officer of New Jersey-based TrialScope, said transparency has picked up over the past few years, particularly as large pharma companies have begun to release information about their own clinical efforts.
In this week’s edition of Movers and Shakers, biopharma companies tap executives to serve in various leadership roles.
After Health and Human Services Secretary Alex Azar, a former executive with Eli Lilly, unveiled a pricing reform that would allow pharma companies to end the rebate system and pass those savings directly to consumers, leaders from across the pharma industry are offering early support for the proposal.
First Light Diagnostics announced the addition of Dr. Peter Kaspar to the company’s board of directors effective January 1, 2019.
Robert Mahley, founder and president of Gladstone Institutes, an internationally-recognized expert on heart disease, cholesterol metabolism and Alzheimer’s disease, is launching a biotech company to focus on Alzheimer’s disease. The company is called GABAeron.
PRESS RELEASES